Our new Japanese recruitment team delivers volunteer panels - already!

Posted:
16
December 2004

Volunteers enjoying a study

Richmond Pharmacology's new dedicated Japanese recruitment team have successfully delivered 2 Japanese panels for Bridging Studies in November and December this year. We are already ahead of target for our Japanese/Caucasian Bridging Studies requirements in 2005.As a result of the continued growth in the demand for Bridging Studies, Richmond Pharmacology have developed a dedicated in-house approach to the recruitment of Japanese volunteer panels.Wendy Galloway, Head of Volunteer Recruitment, commented: “We recognised the need to introduce a stronger means of recruiting Japanese volunteers. Consequently, in September we recruited 5 bilingual Japanese recruitment managers and have introduced a specialist marketing strategy to support this. I am delighted with the results – in just 2 months since the launch we have successfully delivered 2 Japanese volunteer panels. Our campaigns currently stretch across the UK and Germany and through this approach we are already ahead of target for the New Year's requirements. This means we continue to offer our clients a volunteer recruitment guarantee on every Phase I study.”Richmond Pharmacology is Europe's largest provider of Japanese/Caucasian Bridging Studies and has a dedicated Japanese recruitment brand and department. For more information click here.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more